Back to Search Start Over

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes.

Authors :
Eid, Stephanie A.
O'Brien, Phillipe D.
Hinder, Lucy M.
Hayes, John M.
Mendelson, Faye E.
Zhang, Hongyu
Zeng, Lixia
Kretzler, Katharina
Narayanan, Samanthi
Abcouwer, Steven F.
Brosius III, Frank C.
Pennathur, Subramaniam
Savelieff, Masha G.
Feldman, Eva L.
Source :
Biology (2079-7737). Nov2020, Vol. 9 Issue 11, p347. 1p.
Publication Year :
2020

Abstract

Simple Summary: Type 1 and type 2 diabetes can lead to serious health problems that affect many organs including the nerve, the eye, and the kidney. These health problems can be disabling or even life-threatening, and to date, there are no effective therapies that can slow or prevent their development. We studied the effect of empagliflozin, a medication that reduces blood sugar levels and the risk of cardiovascular disease, on the nerve, eye, and kidney in a side-by-side comparison of type 1 and type 2 mouse models. Empagliflozin had no beneficial effects on disease progression in type 2 diabetic mice, but improved nerve function in the type 1 diabetic model, an effect that was accompanied by reduced markers of oxidative injury. These findings support the concept that different mechanisms contribute to nerve damage in type 1 and type 2 diabetes. Our results further support our view that the concept of one therapy will benefit all complications should be abandoned as we pursue more personalized, tissue-specific, diabetes type-specific treatments. Microvascular complications account for the significant morbidity associated with diabetes. Despite tight glycemic control, disease risk remains especially in type 2 diabetes (T2D) patients and no therapy fully prevents nerve, retinal, or renal damage in type 1 diabetes (T1D) or T2D. Therefore, new antidiabetic drug classes are being evaluated for the treatment of microvascular complications. We investigated the effect of empagliflozin (EMPA), an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), on diabetic neuropathy (DPN), retinopathy (DR), and kidney disease (DKD) in streptozotocin-induced T1D and db/db T2D mouse models. EMPA lowered blood glycemia in T1D and T2D models. However, it did not ameliorate any microvascular complications in the T2D model, which was unexpected, given the protective effect of SGLT2 inhibitors on DKD progression in T2D subjects. Although EMPA did not improve DKD in the T1D model, it had a potential modest effect on DR measures and favorably impacted DPN as well as systemic oxidative stress. These results support the concept that glucose-centric treatments are more effective for DPN in T1D versus T2D. This is the first study that provides an evaluation of EMPA treatment on all microvascular complications in a side-by-side comparison in T1D and T2D models. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20797737
Volume :
9
Issue :
11
Database :
Academic Search Index
Journal :
Biology (2079-7737)
Publication Type :
Academic Journal
Accession number :
147263708
Full Text :
https://doi.org/10.3390/biology9110347